Transkaryotic Therapies, Inc.

Ra Pharmaceuticals, Inc.

Shire Human Genetic Therapies, Inc.

The General Hospital Corporation

Takeda Pharmaceutical Company Limited

Douglas A Treco

Richard F Selden

Michael W Heartlein

Alonso Ricardo

Michelle Denise Hoarty

Zhong Ma

Ping Ye

Kristopher Josephson

Nathan Ezekiel Nims

Daniel Elbaum

Zhaolin Wang

Hong Zheng

Kathleen Seyb

Guo-Qing Tang

Ketki Ashok Dhamnaskar

Sarah Jacqueline Perlmutter

Kelley Cronin Larson

Marianne Borowski

Robert P Hammer

Carol M Kinoshita

Kenneth Loveday

Melanie D Williams

Sylvia Tobe

Eberhard Schneider

Peter Wagner

Nicolas Cedric Boyer

Gregor Schurmann

Steven James DeMarco

Frances P Gillispie

Allan M Miller

Paul Anderson

Douangsone D Vadysirisack

Ramin Farzaneh-Far

Vaishnavi Rajagopal

Grace Victoria Parker

Michelle Denise Arata

Michael F Concino

Peter Francis Daniel

Stephen J Duguay

Yili Sun

Thomas J Schuetz

Brian M Hauge

Robert Paul Hammer

Frances P Gillespie

The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.

Modulators of complement activity

The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Modulation of complement activity

The present invention relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics.

The present disclosure relates to polypeptide modulators of complement activity, including cyclic polypeptide modulators. Included are methods of utilizing such modulators as therapeutics. Also provided are methods of measuring C5 and related complexes using C5 binding agents.

The invention provides methods of treating &#x3b1;-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human &#x3b1;-galactosidase A are also included.

Treatment of &#x3b1;-galactosidase a deficiency

The present invention provides Ras modulators including inhibitors and/or antagonists of Ras, Ras binding, and Ras-dependent cell signaling activity. Also provided are methods of utilizing the Ras modulators as therapeutics.

Ras binding peptides and methods of use

Provided herein are, inter alia, methods for linking an mRNA molecule to a polypeptide (e.g., a peptide or a protein) by linking the mRNA molecule to a linking amino acid in the polypeptide, or by linking the mRNA molecule to a linking tRNA to which the polypeptide is attached, via reactions not catalyzed by the ribosome, and methods for making polypeptide libraries. Also provided are mRNA-protein complexes and mRNA-tRNA-protein complexes, libraries containing these complexes, and methods of using these complexes.

Protein and peptide libraries

Growing community of inventors

Arlington, MA, United States of America

Douglas A Treco